skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Lee, Jung-Min ; Cimino-Mathews, Ashley ; Peer, Cody J ; Zimmer, Alexandra ; Lipkowitz, Stanley ; Annunziata, Christina M ; Cao, Liang ; Harrell, Maria I ; Swisher, Elizabeth M ; Houston, Nicole ; Botesteanu, Dana-Adriana ; Taube, Janis M ; Thompson, Elizabeth ; Ogurtsova, Aleksandra ; Xu, Haiying ; Nguyen, Jeffers ; Ho, Tony W ; Figg, William D ; Kohn, Elise C

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2193-2202 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
2
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Material Type:
Artigo 		Adicionar ao Meu Espaço

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, Peter C ; Boss, David S ; Yap, Timothy A ; Tutt, Andrew ; Wu, Peijun ; Mergui-Roelvink, Marja ; Mortimer, Peter ; Swaisland, Helen ; Lau, Alan ; O'Connor, Mark J ; Ashworth, Alan ; Carmichael, James ; Kaye, Stan B ; Schellens, Jan H.M ; de Bono, Johann S

The New England journal of medicine, 2009-07, Vol.361 (2), p.123-134 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
3
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Matulonis, U.A. ; Wulf, G.M. ; Barry, W.T. ; Birrer, M. ; Westin, S.N. ; Farooq, S. ; Bell-McGuinn, K.M. ; Obermayer, E. ; Whalen, C. ; Spagnoletti, T. ; Luo, W. ; Liu, H. ; Hok, R.C. ; Aghajanian, C. ; Solit, D.B. ; Mills, G.B. ; Taylor, B.S. ; Won, H. ; Berger, M.F. ; Palakurthi, S. ; Liu, J. ; Cantley, L.C. ; Winer, E.

Annals of oncology, 2017-03, Vol.28 (3), p.512-518 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Discovery and Characterization of (8S,9R)‑5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl‑1H‑1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro‑3H‑pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Discovery and Characterization of (8S,9R)‑5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl‑1H‑1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro‑3H‑pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Material Type:
Artigo 		Adicionar ao Meu Espaço

Discovery and Characterization of (8S,9R)‑5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl‑1H‑1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro‑3H‑pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent

Wang, Bing ; Chu, Daniel ; Feng, Ying ; Shen, Yuqiao ; Aoyagi-Scharber, Mika ; Post, Leonard E

Journal of medicinal chemistry, 2016-01, Vol.59 (1), p.335-357 [Periódico revisado por pares]

United States: American Chemical Society

Texto completo disponível

Citações Citado por
5
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
Material Type:
Artigo 		Adicionar ao Meu Espaço

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Pilla Reddy, Venkatesh ; Bui, Khanh ; Scarfe, Graeme ; Zhou, Diansong ; Learoyd, Maria

Clinical pharmacology and therapeutics, 2019-01, Vol.105 (1), p.229-241 [Periódico revisado por pares]

United States: John Wiley and Sons Inc

Texto completo disponível

Citações Citado por
6
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

Bendell, Johanna ; Andre, Valerie ; Ho, Alan ; Kudchadkar, Ragini ; Migden, Michael ; Infante, Jeffrey ; Tiu, Ramon V ; Pitou, Celine ; Tucker, Trevor ; Brail, Les ; Von Hoff, Daniel

Clinical cancer research, 2018-05, Vol.24 (9), p.2082-2091 [Periódico revisado por pares]

United States: American Association for Cancer Research Inc

Texto completo disponível

Citações Citado por
7
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

Berge, M. ; Giraud, J. S. ; De Percin, S. ; Puszkiel, A. ; Thomas-Schoemann, A. ; Blanchet, B.

Cancer chemotherapy and pharmacology, 2024-05, Vol.93 (5), p.519-521 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
8
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors

Dhawan, Mallika S ; Bartelink, Imke H ; Aggarwal, Rahul Raj ; Leng, Jim ; Zhang, Jenna Z ; Pawlowska, Nela ; Terranova-Barberio, Manuela ; Grabowsky, Jennifer A ; Gewitz, Andrew ; Chien, Amy J ; Moasser, Mark ; Kelley, Robin K ; Maktabi, Tayeba ; Thomas, Scott ; Munster, Pamela N

Clinical cancer research, 2017-11, Vol.23 (21), p.6400-6410 [Periódico revisado por pares]

United States: American Association for Cancer Research Inc

Texto completo disponível

Citações Citado por
9
Targeting the DNA Repair Pathway in Ewing Sarcoma
Targeting the DNA Repair Pathway in Ewing Sarcoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Targeting the DNA Repair Pathway in Ewing Sarcoma

Stewart, Elizabeth ; Goshorn, Ross ; Bradley, Cori ; Griffiths, Lyra M. ; Benavente, Claudia ; Twarog, Nathaniel R. ; Miller, Gregory M. ; Caufield, William ; Freeman, Burgess B. ; Bahrami, Armita ; Pappo, Alberto ; Wu, Jianrong ; Loh, Amos ; Karlström, Åsa ; Calabrese, Chris ; Gordon, Brittney ; Tsurkan, Lyudmila ; Hatfield, M. Jason ; Potter, Philip M. ; Snyder, Scott E. ; Thiagarajan, Suresh ; Shirinifard, Abbas ; Sablauer, Andras ; Shelat, Anang A. ; Dyer, Michael A.

Cell reports (Cambridge), 2014-11, Vol.9 (3), p.829-840 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
10
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

RAJAN, Arun ; CARTER, Corey A ; SPENCER, Shawn ; FIGG, William Douglas ; GIACCONE, Giuseppe ; KELLY, Ronan J ; GUTIERREZ, Martin ; KUMMAR, Shivaani ; SZABO, Eva ; YANCEY, Mary Ann ; JIUPING JI ; MANNARGUDI, Baskar ; WOO, Sukyung

Clinical cancer research, 2012-04, Vol.18 (8), p.2344-2351 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (162)

Data de Publicação 

De até
Refinar
  1. Antes de1993  (11)
  2. 1993Até2001  (16)
  3. 2002Até2009  (33)
  4. 2010Até2017  (63)
  5. Após 2017  (43)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (164)
  2. Japonês  (25)
  3. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.